The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review

Abstract

Ulcerative colitis (UC) is an inflammatory condition that generally affects the rectum and extends proximally into the colon in a continuous, distal-to-proximal pattern. Surgical resection (total proctocolectomy) is the only cure for UC and is often necessary in managing complicated or refractory disease. However, recent advances in biologically targeted therapies have resulted in improved disease control, and surgery is required in only a fraction of cases. This ever-increasing array of options for medical management has added complexity to surgical decision-making. In some circumstances, the added time required to ensure failure of medical therapy can delay colectomy in patients who will ultimately need it. Indeed, many patients with severe disease undergo trials of multiple medical therapies prior to considering surgery. In severe cases of UC, continued medical management has been associated with a delay to surgical intervention and higher rates of morbidity and mortality. Biomarkers represent a burgeoning field of research, particularly in inflammatory bowel disease and cancer. This review seeks to highlight the different possible settings for surgery in UC and the role various biomarkers might play in each.

Artificial Intelligence Analysis of Ulcerative Colitis Using an Autoimmune Discovery Transcriptomic Panel

“…Detailed descriptions of the clinicopathological features of ulcerative colitis have been recently published [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. A gene that was highlighted in this research was CD274 ( PD-L1 ).…”

Artemisinin Alleviates Intestinal Inflammation and Metabolic Disturbance in Ulcerative Colitis Rats Induced by DSS

“…In recent years, with the development of industrialization, the incidence of UC has shown a significant upward trend in the world [ 21 ]. Although studies have shown that multiple factors such as genetics, immunity, environment, and intestinal microecology may lead to the occurrence of UC, the specific mechanism of UC is still unclear [ 22 , 23 ].…”

Clinical and biochemical status of patients with ulcerative collitis

“…У пациентов с ЯК по сравнению с клинически здоровыми лицами выявлено снижение концентрации общего белка в крови на 25 %, свидетельствующее об увеличении интенсивности процессов катаболизма над анаболическими процессами, что сопровождается в ряде случаев незначительным повышением активности трансаминаз и концентрации мочевины. Данные проявления являются следствием острого воспалительного процесса, а также могут возникать при нарушениях пищевого режима и мальабсорбции, что при наличии ЯК может сопровождать заболевание, усиливая его тяжесть и снижая эффективность терапии [15].…”